StockData
Inhibrx Biosciences, Inc. logo

Inhibrx Biosciences, Inc. (INBX) stock

INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$83.30−4.45 (-5.07%)

Close on Nov 13, 2026Market cap $1.23BP/E –Yield –

Inhibrx Biosciences operating margin

Operating margin is operating income as a percentage of revenue.

Inhibrx Biosciences's operating margin for the twelve months ending Dec 31, 2025 was -10386.5%. For fiscal 2025 it was -10386.5%, against -165724.0% the year before. The highest annual figure on record is -330.9% in fiscal 2019.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-10386.5%+155337.5
FY2024Dec 31, 2024-165724.0%−153545.1
FY2023Dec 31, 2023-12178.9%−6288.6
FY2022Dec 31, 2022-5890.4%−4831.5
FY2021Dec 31, 2021-1058.8%−535.5
FY2020Dec 31, 2020-523.3%−192.4
FY2019Dec 31, 2019-330.9%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-1586.8%+3816.5
Q2 FY2025Jun 30, 2025-2106.8%+36403.2
Q4 FY2024Dec 31, 2024-49928.0%+87868.7
Q2 FY2024Jun 30, 2024-160898.0%+96549.1
Q4 FY2023Dec 31, 2023-5403.2%+7553.0
Q3 FY2023Sep 30, 2023-38510.1%−27717.6
Q2 FY2023Jun 30, 2023-137796.7%−132930.7
Q1 FY2023Mar 31, 2023-257447.1%−254323.6
Q4 FY2022Dec 31, 2022-12956.2%−12276.8
Q3 FY2022Sep 30, 2022-10792.4%−10049.9
Q2 FY2022Jun 30, 2022-4866.0%−2790.4
Q1 FY2022Mar 31, 2022-3123.5%−1036.0
Q4 FY2021Dec 31, 2021-679.4%−63.2
Q3 FY2021Sep 30, 2021-742.5%−478.9
Q2 FY2021Jun 30, 2021-2075.6%−1561.4
Q1 FY2021Mar 31, 2021-2087.5%−67.9
Q4 FY2020Dec 31, 2020-616.2%+5640.0
Q3 FY2020Sep 30, 2020-263.7%+806.7
Q2 FY2020Jun 30, 2020-514.1%–
Q1 FY2020Mar 31, 2020-2019.6%–
Q4 FY2019Dec 31, 2019-6256.3%–
Q3 FY2019Sep 30, 2019-1070.3%–

More Inhibrx Biosciences figures

See a number that looks wrong?